A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
Clinical trial NCT01067521 · COMPLETED
Trial details
- NCT number
- NCT01067521
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2010-06-22
- Primary completion
- 2012-05-08
- Enrollment
- 1404
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.